Redmile Group LLC Has $1.81 Million Stock Position in Ventyx Biosciences, Inc. $VTYX

Key Points

• Redmile Group LLC significantly increased its holdings in Ventyx Biosciences by 1,164.1% in the first quarter, now owning 1,569,793 shares worth $1,805,000.
• Wall Street analysts have upgraded Ventyx Biosciences from a "sell" to a "hold" rating, with the stock averaging a rating of "Moderate Buy" and a price target of $7.50.
• Ventyx Biosciences has reported a quarterly EPS of ($0.38), surpassing expectations, while the stock's market cap is currently $171.14 million.

Redmile Group LLC grew its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 1,164.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,569,793 shares of the company's stock after buying an additional 1,445,615 shares during the quarter. Redmile Group LLC owned approximately 2.21% of Ventyx Biosciences worth $1,805,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VTYX. Bank of America Corp DE increased its stake in shares of Ventyx Biosciences by 376.4% in the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock valued at $9,359,000 after buying an additional 3,376,446 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Ventyx Biosciences in the fourth quarter valued at $3,903,000. Millennium Management LLC increased its stake in shares of Ventyx Biosciences by 369.7% in the fourth quarter. Millennium Management LLC now owns 1,281,629 shares of the company's stock valued at $2,807,000 after buying an additional 1,008,760 shares in the last quarter. Monaco Asset Management SAM increased its stake in shares of Ventyx Biosciences by 372.7% in the first quarter. Monaco Asset Management SAM now owns 1,134,444 shares of the company's stock valued at $1,305,000 after buying an additional 894,444 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in Ventyx Biosciences by 72.1% in the fourth quarter. Two Sigma Advisers LP now owns 800,800 shares of the company's stock worth $1,754,000 after purchasing an additional 335,400 shares during the period. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Ventyx Biosciences Stock Performance

VTYX traded down $0.08 during midday trading on Friday, reaching $2.52. 429,444 shares of the company were exchanged, compared to its average volume of 569,336. Ventyx Biosciences, Inc. has a one year low of $0.78 and a one year high of $3.39. The stock has a market capitalization of $179.70 million, a P/E ratio of -1.50 and a beta of 0.95. The stock's 50-day simple moving average is $2.65 and its 200 day simple moving average is $1.92.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.07. On average, research analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Ventyx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Ventyx Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.